# Summary of Product Characteristics

**1-NAME OF THE MEDICINAL PRODUCT (FPP)**

Parol®

*Paracetamol*

**1.1 Strength**

250 mg/5ml

**1.2 Pharmaceutical form**

Oral suspension

**2- QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml of suspension contains 50 mg of paracetamol.

 Each dose of 5 ml contains 250 mg paracetamol.

Excipients with known effect

Ponceau red (E124): 0.5mg/5ml (0.1mg/ml)

Methylparahydroxybenzoate : 5.4 mg/5ml (1,1 mg/ml)

 Sucrose 2.5g/5ml (500 mg/ml)

 For the full list of excipients, see section 6.1

**3- PHARMACEUTICAL FORM**

Oral suspension

Homogeneous suspension, pink colour, strawberry flavour.

**4- CLINICAL PARTICULARS**

**4.1 Therapeutic indications**

Relieve of mild and moderate pain and reducing fever.

Paracetamol is indicated for the short-term symptomatic treatment from the age of 3 months on.

Parol® Suspension is used for symptomatic treatment of pain associated with conditions such as headaches, toothaches, migraine, teething, neuralgia, post‐traumatic, post‐operative pains and musculoskeletal pains.

Furthermore, reduce fever and relieve pains and aches associated with conditions such as flu, cold, sore throat, sinusitis, and other acute febrile illnesses.

**4.2 Posology and mode of administration**

**4.2.1 Posology**

* The recommended daily dose of paracetamol is approximately 60 mg / kg / day, divided into 4 or 6 doses ; approximately 15 mg / kg every 6 hours or 10 mg / kg every 4 hours.

| Body weight | Approximatively dose of paracetamol per unique intake, maximally to be repeated after 6 hours if necessary  | Approximatively volume of Parol 250mg/5ml per unique intake, maximally to be repeated after 6 hours if necessary |
| --- | --- | --- |
| Less than 7 kg | Up to 100 mg | 2 ml |
| Between 7 and 10 kg | 100 to 150 mg | 2 to 3 ml |
| Between 10 and 16 kg | 150 to 250 mg | 3 to 5 ml |
| Between 16 and 20 kg | 225 to 300 mg | 5 to 6 ml |
| Between 20 and 30 kg | 300 to 450 mg | 6 to 9 ml |
| Over 30 kg  | 500 mg | 10 ml |

* The maximum daily dose should not be exceeded because of the risk of severe liver injury.

**4.2.2 Special populations**

See section 4.4

**4.2.2 Paediatric population**

* Paracetamol can be used from the age of 3 months. In children under 3 year’s paracetamol should be used only on the recommendation of the doctor.
* In children, it is imperative to respect the dosages defined according to the weight of the child and thus to choose the dose in ml of appropriate oral suspension. The approximate ages by weight are given for information.

**4.2.3 Method of administration**

Oral use, dose-administration by means of a measuring device.

**4.3 Contraindications**

Parol suspension is contraindicated in case of hypersensitivity or allergy to the active substance or to any of the excipients listed in section 6.1.

**4.4 Special warning and precautions for use**

**4.4.1 General information**

Prolonged, frequent or simultaneous use of other products containing paracetamol is not recommended.

In case of **overdose** (several daily doses at one time) severe liver failure can occur, with loss of consciousness. In this case, it is imperative to perform an intravenous infusion with acetylcysteine in an intensive care unit. See also section 4.9.

After long-term treatment (> 3 months) reactive headaches can develop. These headaches caused by the abuse of analgesics (MOH or medicine-overuse headache) should not be treated by increasing the dose. In these cases, the use of analgesics should be stopped on the advice of a doctor. Sudden discontinuation after prolonged treatment with high of doses analgesics may lead to headaches, fatigue, muscle aches, nervousness and reflex symptoms. These withdrawal symptoms disappear within a few days.

Parol suspension contains methyl parahydroxybenzoate which may cause allergic reactions (possibly delayed).

Parol suspension contains the colourant ponceau red (E124) which may cause allergic reactions.

Parol suspension contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine.

**Renal and hepatic insufficiency**

* Administration of paracetamol to patients with moderate to severe renal impairment may result in accumulation of conjugated derivatives.
* The risk of liver toxicity is significantly increased in chronic alcohol abuse. Dosage reduction is therefore required in these patients.
* In elderly patients, liver and kidney tests should be performed to detect early liver or kidney failure.
* Caution is recommended in patients with proven hepatic impairment. It is the same in patients consuming substances inducing liver enzymes (alcohol, barbiturates, anti-epileptics). In these cases, accumulation of the toxic metabolites of paracetamol may aggravate or lead to liver injury. The risk of hepatic toxicity is considerably increased in chronic alcohol abuse. Dosage reduction is therefore required in these patients.
* Special caution and adherence to the recommended dosage are essential in epileptic children treated with barbiturates, phenytoin, carbamazepine or lamotrigine.

**4.4.2 Paediatric population**

No other special precautions required

**4.5 Interactions with other medicinal products and other forms of interactions**

**4.5.1 General information**

* In case of overdose of paracetamol, alcohol, barbiturates, phenytoin, carbamazepine and isoniazid may increase the risk of liver damage.
* Because of its lack of action on the gastric mucosa, paracetamol can be given to ulcer patients, or be associated, for a limited time, with nonsteroidal anti-inflammatory drugs.
* Its low plasma protein binding allows its association with anticoagulants. However, taking paracetamol for a prolonged period may increase the risk of bleeding. In this case, regular monitoring of the International Normalised Ratio (INR) is recommended.
* Paracetamol absorption may be increased if combined with metoclopramide, and decreased if combined with cholestyramine or activated charcoal.
* Due to the risk of decreased leukocyte (leukopenia) levels when concomitant administration of paracetamol and AZT (zidovudine), simultaneous administration will only be with medical advice. Simultaneous administration of diflunisal and paracetamol increases plasma levels of paracetamol by approximately 50%.

**4.5.2 Additional information on special populations**

No additional information

**4.5.3 Paediatric population**

Special caution and adherence to the recommended dosage are essential in epileptic children treated with barbiturates, phenytoin, carbamazepine or lamotrigine.

**4.6 Fertility, pregnancy and lactation**

**4.6.1 Fertility**

The available clinical information on the effect of paracetamol on fertility is insufficient.

**4.6.2 Pregnancy**

The results of well conducted epidemiological studies seem to exclude the deleterious effects of paracetamol on pregnancy or on the foetus or new-born. Paracetamol can be used in pregnant women.

**4.6.3 Lactation**

After oral administration, paracetamol is excreted in breast milk in small amounts. There were no reports of adverse effects on infants at recommended therapeutic doses in lactating women.

**4.7 Effects on the ability to drive and use machines**

Paracetamol has no or negligible effect on the ability to conduct vehicles or to use machines.

**4.8 Undesirable effects**

In therapeutic doses, paracetamol has only few undesirable effects

The frequencies of adverse reactions reported with paracetamol are defined as:

* very common (≥ 1/10)
* common (≥ 1/100 to < 1/10)
* uncommon (≥ 1/1,000 to < 1/100)
* rare (≥ 1/10,000 to < 1/1,000)
* very rare ( < 1/10,000)
* not known (cannot be estimated from the available data)

| **System organ class** | **Frequency** | **Undesirable effects** |
| --- | --- | --- |
| Blood and lymphatic system disorders | Rare: | Thrombocytopenia, leukopenia, pancytopenia, neutropenia, haemolytic anaemia, agranulocytosis |
| Not known | Anaemia |
| Immune system disorders | Rare | Allergic reactions |
| Very rare | Allergic reactions requiring treatment stop |
| Not known | Anaphylactic choc |
| Metabolism and nutrition disorders | Very rare: | Hypoglycaemia |
| Psychiatric disorders | Rare | Depression\*, confusion, hallucinations |
| Nervous system disorders | Rare | Tremor \*, headache \* |
| Eye disorders | Rare | Abnormal vision |
| Cardiac disorders | Rare | Oedema |
| Respiratory, thoracic and mediastinal disorders | Not reported | Not reported |
| Gastrointestinal disorders | Rare | Haemorrhage \*, abdominal pain \*, diarrhoea \*, nausea, vomiting, constipation |
| Hepatobiliary disorders | Rare | Decreased hepatic function, liver failure, hepatic necrosis, jaundice |
| Very rare: | Hepatotoxicity |
| Not known | Hepatitis |
| Skin and subcutaneous tissue disorders | Rare | Pruritus, rash, sweating, purpura, angioedema, urticaria |
| Very rare  | Severe skin reactions |
| Renal and urinary disorders | Very rare | Sterile pyuria (cloudy urine) and renal adverse events |
| Not Known | Neuropathies (interstitial nephritis, tubular necrosis) with long-term use of high doses |
| General disorders and administration site conditions | Rare | Dizziness (except vertigo), malaise, pyrexia, sedation, drug interaction\* |
| Injury, poisoning and procedural complications | Rare  | Overdose and intoxication |

\*Without specifications

**4.9 Overdose**

**An overdose with paracetamol may be fatal.**

* Symptoms of paracetamol intoxication include nausea, vomiting, anorexia, pallor, and abdominal pain. These symptoms usually appear within 24 hours of taking the overdose.
* A paracetamol overdose of 10 g or more in a single dose in adults or 150 mg / kg body weight in a single dose in children results in hepatic cytolysis that may result in complete and irreversible necrosis resulting in hepatocellular insufficiency, metabolic acidosis, and encephalopathy may lead to coma and death.
* At the same time, hepatic transaminases (ASAT, ALT), lactic dehydrogenase, and bilirubin levels were observed to increase, with prothrombin levels decreasing 12 to 48 hours after ingestion of the overdose.
* Clinical signs of liver injury usually appear after two days and peak after 4-6 days. Even in the absence of severe hepatic injury, acute renal failure with acute tubular necrosis may occur.
* Other non-hepatic symptoms of paracetamol overdose may be myocardial alterations and pancreatitis.

**Emergency treatment**

* Immediate hospitalization.
* After an overdose, a blood sample should be taken to determine the paracetamol level as soon as possible before starting treatment.
* Rapid evacuation of the ingested product by gastric lavage, then administration of active charcoal (adsorbent) and sodium sulphate (laxative).
* Dialysis may reduce the plasma concentration of paracetamol.
* The treatment consists of the administration of the antidote N-acetylcysteine (NAC), intravenously or orally, if possible before the tenth hour after ingestion of the overdose. NAC treatment may result a protective effect even after 10 hours when given as a prolonged treatment.
* Symptomatic treatment.
* Liver tests should be performed at the beginning of treatment and repeated every 24 hours. In most cases, hepatic transaminases will return to normal levels within one to two weeks, and liver function will be fully restored. However, in very rare cases, liver transplantation may be indicated.

**5- PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group other analgesics and antipyretics, anilides

ATC code: N02BE01

Paracetamol has both analgesic and antipyretic effect. However, it has no anti-inflammatory effect. The mechanism of analgesic action has not been fully determined. The main action of paracetamol is the inhibition of cyclooxygenase, an important enzyme in the synthesis of prostaglandin. Cyclooxygenase in the central nervous system is more sensitive to paracetamol than peripheral cyclooxygenase, which is why paracetamol has antipyretic and analgesic efficacy. Paracetamol probably produces antipyretics by acting centrally on the hypothalamic centre of thermoregulation.

**5.2 Pharmacokinetic properties**

**Absorption**

Paracetamol is rapidly and completely absorbed after oral administration. Peak plasma concentration is reached within two hours.

**Distribution**

Paracetamol is poorly bound to plasma proteins (20 to 50%) and its diffusion is rapid.

**Metabolism and elimination**

Paracetamol is metabolized in the liver and is then eliminated in the urine, mainly in two forms: glucuronoconjugate (60 to 80%) and sulfoconjugate (20 to 40%). A small fraction (less than 4%) is transformed in the liver by cytochrome P 450 into a metabolite that is involved in the paracetamol hepatotoxicity. At therapeutic doses, this toxic metabolite is eliminated by conjugation with glutathione. The conjugation capacity is not modified in the elderly and the kinetics is linear for doses up to 7 g. In case of massive overdose, the conjugation capacity is exceeded, and the fraction of the hepatotoxic metabolite increases.

**5.3 Preclinical safety data**

* In toxicity studies in rats and mice, gastrointestinal lesions, changes in blood counts, degeneration of hepatic and renal parenchyma, and necrosis have been observed. These changes are attributed to both the mechanism of action and the metabolism of paracetamol.
* Extensive research has not shown any relevant genotoxic risk of paracetamol at therapeutic dose.
* Long-term studies in rats and mice showed no relevant carcinogenic effects at non-hepatotoxic doses of paracetamol.
* Paracetamol passes the placental barrier.
* Studies in animals have shown no reproductive toxicity.

**6- PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

* Methyl hydroxybenzoate
* Saccharin sodium
* Sucrose
* Carmellose sodium
* Microcrystalline cellulose with carmellose sodium
* Glycerol
* Polysorbate 80
* Strawberry Essence
* Ponceau 4R (E124)
* Purified water

**6.2 Incompatibilities**

None known

**6.3 Shelf life**

3 years

**6.4 Special precautions for storage**

Store below 30°C, in original package to protect from light.

Shake well before use.

**6.5 Nature and contents of container**

Amber coloured glass bottle containing 100 ml of suspension, closed with a white plastic screw-cap.

 Box with one labelled bottle, a patient leaflet and a plastic dosing device.

**6.6 Special precautions for disposal and other handlings**

No special requirements for disposal.

Any unused product or waste material should be disposed of in accordance with local requirements.

**7- MARKETING AUTHORISATION HOLDER AND MANUFACURING SITE ADDRESS**

**7.1 Marketing Authorisation Holder**

Dafra Pharma GmbH, Mühlenberg 7, 4052 Bâle, Suisse.

**7.2 Manufacturer**

Atabay Kimya San.ve.Tic. A.Ş

Dilovası Sanayi Bölgesi, 4.Kısım Sakarya Caddesi, No:28 Gebze/KOCAELİ, Turkey

**8- MARKETING AUHORISATION NUMBER**

See list of MAs per country

**9- DATE OF FIRST REGISTRATION**

See list of MAs per country

**10- DATE OF REVISION OF TEXT**

July 2020